[6] Satoh T, Xu RH, Chung HC, et al. Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study. J Clin Oncol. 2014 Jul 1;32(19):2039-49. [7] Thuss-Patience PC, ...
[2]Sammons SL, Leone JP, Sanglier Thibaut, et al. Brain metastases in metastatic breast cancer: prevalence per line of treatment and cumulative incidence in a cohort of 18075 real-world patients. 2023 SABCS PS11-01. [3]Yamanaka T, Niikura N, Nakayama T, et al. Trastuzumab deruxtecan for...
2、X. Wang, J. Huang. Pyrotinib in combination with docetaxel as first-line treatment for HER2-positive metastatic breast cancer(PANDORA): A single-arm, multicenter phase II trial. Abstract 239P. Annals of Oncology(2022)33(suppl_7): S88-S121. 10.1016/annonc/annonc1040. 4、Xu B, Yan M...
13、Hua, Xin et al. Trastuzumab Plus Endocrine Therapy or Chemotherapy as First-line Treatment for Patients with Hormone Receptor-Positive and HER2-Positive Metastatic Breast Cancer (SYSUCC-002). Clinical cancer research : an official journal of the Am...
FIRST LINE TREATMENTHER2METASTATIC BREAST CANCERTRASTUZUMABThe human epidermal growth factor receptor II (HER2) plays an important role in the development of breast cancer. Targeting HER2 with monoclonal antibodies drastically improved treatment outcomes in breast cancer patients with HER2 overexpression. ...
[7]Elimova, E. et al. 1423P Zanidatamab + chemotherapy for first-line (1L) treatment of HER2+ advanced or metastatic gastro-oesophageal adenocarcinoma (mGEA): New and updated data from a phase II trial. Annals of Oncology, Vo...
[11] André F, Hee Park Y, Kim SB, et al. Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2023 May 27;401(10390):1773-1785. ...
9. Boix-Perales H, Borregaard J, Jensen K B, et al. The European Medicines Agency Review of Pertuzumab for the treatment of adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer: summary of the scientific assessment of the committee for medicinal products for...
use prior to surgery (neoadjuvant treatment) in people with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (tumor is greater than 2 cm in diameter or node-positive). PERJETA should be used as part of a complete treatment regimen for early breast cancer. ...
HERCEPTIN HYLECTA in combination with the chemotherapy drug paclitaxel is approved for the first line treatment ofHumanEpidermal growth factorReceptor2-positive (HER2+) metastatic breast cancer HERCEPTIN HYLECTA alone is approved for the treatment of HER2-positive breast cancer in patients who have receiv...